伊马替尼(Gleevec(Registered Trademark))治疗慢性粒单核细胞白血病与非典型慢性髓系白血病
该数据集来自 clinicaltrials.gov,聚焦伊马替尼(Gleevec(Registered Trademark))用于治疗慢性粒单核细胞白血病(CMML)与非典型慢性髓系白血病(CML)的研究

基本信息
资源简介
伊马替尼(Gleevec(Registered Trademark))治疗慢性粒单核细胞白血病与非典型慢性髓系白血病
该数据集来自 clinicaltrials.gov,聚焦伊马替尼(Gleevec(Registered Trademark))用于治疗慢性粒单核细胞白血病(CMML)与非典型慢性髓系白血病(CML)的研究。研究目的是评估伊马替尼在改善CMML与非典型CML患者血细胞计数方面的安全性和有效性。源站描述指出,尽管已有多种药物治疗这些疾病,但多数患者无应答;伊马替尼在临床试验中已显示可使慢性期CML患者获得高应答率,并对部分CMML、非典型CML及特发性高嗜酸性粒细胞综合征(HES)患者有效。该数据可用于白血病治疗相关研究(来源 clinicaltrials.gov)。
【数据内容】
源站描述(机器翻译,仅供参考):疾病:慢性粒单核细胞白血病、慢性髓系白血病。本研究的目的是评估伊马替尼在改善慢性粒单核细胞白血病(CMML)和非典型慢性髓系白血病(CML)患者血细胞计数方面的安全性和有效性。尽管已有多种药物用于治疗这些疾病,但大多数患者对治疗无应答。伊马替尼已在临床试验中显示可使慢性期CML患者获得高应答率。伊马替尼也已被证明可有效诱导部分CMML和非典型CML患者的应答,并且对特发性高嗜酸性粒细胞综合征(HES)——另一种骨髓增殖性疾病——的部分患者也有效。由于已证明患有几种不同骨髓增殖性疾病的患者对伊马替尼出现显著应答,我们……
【主题与分类】
主题标签:Chronic Myelomonocytic Leukemia、Chronic Myelogenous Leukemia。本站分类:肿瘤/白血病。
【获取与许可】
源站页面:https://clinicaltrials.gov/study/NCT00079313
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站:https://clinicaltrials.gov/study/NCT00079313
标准获取流程:
- 访问源站链接,注册/登录账号;
- 进入数据集详情页,按页面指引申请权限或直接下载;
- 部分平台提供 SDK,例如:
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelogenous Leukemia. The purpose of this study is to evaluate the safety and effectiveness of imatinib for improving blood counts in patients with chronic myelomonocytic leukemia (CMML) and atypical chronic myelogenous leukemia (CML). Although a number of agents have been used to treat these diseases, most patients do not respond to treatment. Imatinib has been shown in clinical trials to induce high rates of responses in patients with chronic phase CML. Imatinib has also been shown to be effective in inducing responses in a subset of patients with CMML and atypical CML and is also effective in a subset of patients with idiopathic hypereosinophilic syndrome (HES), another myeloproliferative disorder. Because patients with several different myeloproliferative diseases have been shown to experience dramatic responses to imatinib, we would like to determine what proportion of patients with atypical myeloproliferative diseases (CMML and atypical CML) will respond to this agent. Prior to enrollment, a thorough clinical evaluation will be performed. A baseline bone marrow will be obtained to exclude acute leukemia or lymphoma and to assess the degree and nature of the myeloproliferation. In order to minimize bone marrow suppression, other myelosuppressive drugs will be tapered and discontinued during the first week of therapy with imatinib. Complete blood counts will be performed weekly for the first month and every other week thereafter. Clinical assessments will be performed every three months to assess for continued response.
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




